US EditionMetsera: Why Pfizer And Novo Nordisk Fought Hard Over This Obesity Drug Developer (MTSR)
5 Articles
5 Articles
The Covid vaccine maker has struck a deal with Metsera to gain access to new obesity drugs. Pfizer is looking for new sources of growth after declining vaccine revenue, and this could be its opportunity. Metsera is a smaller biopharmaceutical company focused on metabolic diseases. The deal will give it funding, manufacturing capacity and access to Pfizer’s global sales network. This article is for subscribers only. You have 71% left to read.
Pfizer Acquires Metsera for $10 Billion After Novo Nordisk Withdraws from Bidding
Pfizer has successfully secured the acquisition of Mets […] The post Pfizer Acquires Metsera for $10 Billion After Novo Nordisk Withdraws from Bidding first appeared on GeneOnline News. The post Pfizer Acquires Metsera for $10 Billion After Novo Nordisk Withdraws from Bidding appeared first on GeneOnline News.
3:36 PM Investors are breathing a modest sigh of relief now that Novo Nordisk has withdrawn from the battle for the biotech company Metsera. Attention now shifts to Friday, when an internal power struggle...
Novo Nordisk - Wrestling for obesity specialist Metsera: Pfizer wins against Novo Nordisk AUTOS China loosens export rules for Nexperia chips to Europe HFG Hellofresh has rejected a report of shortseller Grizzly Research "decisive" HNR1 Hannover Re increases after very good business performance Profit target for 2025 HYQ Hypoport with profitable growth in 9M/25 KRN Krones defies US tariffs. "The markets are robust, we will continue to grow" (HB)…
Coverage Details
Bias Distribution
- 100% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
